MTEC understands the importance of sharing technical requirements as soon as possible with both members and to potential consortium members in order to allow the maximum possible time to prepare, team, and identify both public and private solicitation sponsors. Draft Request for Project Proposals will be shared via email upon request and this website. Understand that this information is draft in nature and changes could occur prior to publication of final documents. For specific Request for Project Information or Request for Project Proposal inquiries, please direct your correspondence to the following contacts:
- Questions concerning contractual, cost or pricing should be directed to the MTEC Contracts Manager, Ms. Lisa Fisher, email@example.com
- Technology Readiness Levels (TRLs) for most proposed projects must be identified and included with the Technical Proposal. TRL definitions are provided here. Technical related questions should be directed to the MTEC Director of Research, Dr. Lauren Palestrini, Ph.D., firstname.lastname@example.org
- Questions concerning membership should be directed to Ms. Stacey Lindbergh, MTEC Executive Director, email@example.com
- All other questions should be directed to Ms. Polly Graham, MTEC Program Manager, firstname.lastname@example.org
Extracorporeal Life Support (ECLS)
Due: April 28, 2017, 12:00pm EDT
The U.S. Army Medical Research and Materiel Command (USAMRMC) envisions potential future battlefield scenarios of prolonged field care, which will result in the presentation of critically ill patients with acute lung injury (ALI) and acute kidney injury (AKI) far-forward on the battlefield. The response to this scenario will include deploying lightweight, rugged, user-friendly extracorporeal life support (ECLS) devices to Field Hospitals (Role of Care 3) and to transport patients during fixed wing medical evacuation. MTEC’s upcoming program announcement will request proposals to build ECLS devices that integrate the two functions of respiratory and renal support (including extracorporeal blood purification) into one platform. These devices will replace all or part of the function of the lungs for patients with acute respiratory distress syndrome or other types of pulmonary failure, and/or of the function of the kidneys for patients with AKI. This combination device increases its practicality on the battlefield, where every ounce of weight and cubic foot of space is coveted. MTEC will issue a staged competition that proceeds from white papers, to a down selected set of schematics, and finally to a prototype build that would undergo testing in an animal model. The ultimate objective is to produce a product that could reach FDA approval and be bought to bear on improving far forward battlefield trauma care and evacuation.
Here is the Request for Project Proposal: MTEC Solicitation for ECLS (Revision 3)
Combating Antibiotic Resistant Bacteria (CARB) Request for Project Information
Due: May 12, 2017, 11:59 pm EDT
The use of antibiotics saves millions of lives each year around the world. Unfortunately indiscriminant use and lack of compliance with treatment guidelines have led to conditions for accumulation of mutations in bacteria that have caused drug resistance, resulting in a significant decrease in the number of available drugs effective to treat both rare and common bacterial infections. The rise in antibiotic resistance threatens various aspects of life, including both human and animal health, the agriculture industry, the economy, and the treatment of post-surgical infection from elective and life-saving medical procedures. Therefore, there is a critical need to develop novel antibiotics, other therapeutics, and, vaccines to combat infection by antibiotic-resistant bacteria and improve medical surveillance and diagnostic tests for the identification and characterization of antibiotic-resistant bacteria. Advancement in these areas will hopefully make a major impact by strengthening national and international healthcare for humans and animals, public health, agriculture practices, food safety, and research, development and manufacturing.
This MTEC Request for Project Information (RPI) is generally focused on the development of technologies (i.e., biosurveillance, diagnostic tests, antibiotics, vaccines, and other therapeutics) that combat antibiotic-resistance. The use of interdisciplinary approaches including systems biology and synthetic biology to advance prototype development efforts to combat antibiotic resistance are encouraged but not required. Examples of specific areas of interest are included in the full RPI. Project information papers must use the template provided in the RPI and be submitted by 11:59 pm on May 12, 2017 via email to email@example.com.
Please find the details of this RPI here: Combating Antibiotic-Resistant Bacteria (CARB) RPI
Permanent Vascular Repair (PVR)
Due: May 10, 2017, 12:00pm EDT
The Medical Technology Enterprise Consortium (MTEC) is excited to post this announcement for a Request for Project Proposals (RPP) focused on Permanent Vascular Repair (PVR) – the development of products that can serve as permanent arterial and/or venous grafts for reconstruction and repair of traumatic injuries.
Extremity trauma is one of the most common battlefield injuries. Through advances in early field intervention and resuscitation, such injuries have become increasingly survivable. Despite progress, extremity injuries can be devastating with complex injuries to the vasculature, bone, connective tissues, muscle, and nerves. Approximately 50% of patients with complex extremity injuries have severely impaired limb function. These injuries are commonly associated with long term complications and poor functional recovery. In fact, at the same age, military personnel have doubled the rate of post-traumatic osteoarthritis compared to individuals in the civilian population. Severe extremity trauma with initial limb salvage leads to delayed amputation in approximately 14% of patients, typically following many months of repeated surgeries and attempts at rehabilitation. Only 20% of wounded military personnel who experience severe extremity trauma are ultimately able to return to service.
The field of reconstructive surgery following extremity trauma is largely characterized at present by the need for multiple, staged reconstructive procedures, and the use of often scarce autologous tissue with frequently suboptimal results, and low rates of return to duty. In many cases, the best that can be hoped for is to prepare the damaged limb for prosthetic attachment. Optimal solutions would not only provide more durable repairs, but reduce the need autologous tissue and number of surgical procedures.
This RPP seeks proposals from entities developing products that can serve as permanent arterial and/or venous grafts for reconstruction and repair of traumatic injuries. It is recognized that products intended for other indications could be repurposed. MTEC is seeking products near FDA approval or in development beyond Phase 1 or feasibility clinical trials (at a minimum of Technology Readiness Level 5). Prototypes must demonstrate potential to fill an identified capability gap in permanent vascular repair beginning at forward echelons of medical care. At a minimum, it is expected that interested parties will either manufacture or be able to procure products with sufficient clinical safety data to support proceeding into clinical trials. Proposals must aim to demonstrate significant technology advancement toward regulatory approval for a vascular reconstruction indication. Types of proposed activities that are of interest include, but are not limited to regulatory filings, manufacturing, clinical trials in trauma patients or related surrogate populations, and data needed for regulatory approval.
The initial period of performance will be 12 months, with option years to pursue follow-on clinical prototype maturation. Overall costs for an initial award may range from $350,000-$650,000. Initial proposed efforts must include FDA engagement on clinical and manufacturing, with follow-on efforts to be determined based on feedback received. The initial award is not intended to support basic research or research involving human subjects, but follow-on awards may require clinical trials.
Here is the Request for Project Proposal: MTEC Solicitation for Permanent Vascular Repair (PVR)